CL2015002560A1 - Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal. - Google Patents

Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal.

Info

Publication number
CL2015002560A1
CL2015002560A1 CL2015002560A CL2015002560A CL2015002560A1 CL 2015002560 A1 CL2015002560 A1 CL 2015002560A1 CL 2015002560 A CL2015002560 A CL 2015002560A CL 2015002560 A CL2015002560 A CL 2015002560A CL 2015002560 A1 CL2015002560 A1 CL 2015002560A1
Authority
CL
Chile
Prior art keywords
treating
nail unit
composition
disorder
disease
Prior art date
Application number
CL2015002560A
Other languages
English (en)
Inventor
Jay E Birnbaum
Bruce Lerman
Original Assignee
Hallux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hallux Inc filed Critical Hallux Inc
Publication of CL2015002560A1 publication Critical patent/CL2015002560A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un metodo para tratar una enfermedad o trastorno de la unidad ungueal, porque comprende proporcionar un dispositivo compuesto por un aplicador y una composicion que comprende un agente activo insertar el aplicador de forma subungueal y depositar la composicion de forma subungueal y regimen de dosificacion.
CL2015002560A 2013-03-14 2015-09-10 Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal. CL2015002560A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784065P 2013-03-14 2013-03-14
US201361877229P 2013-09-12 2013-09-12

Publications (1)

Publication Number Publication Date
CL2015002560A1 true CL2015002560A1 (es) 2017-04-28

Family

ID=50349975

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002560A CL2015002560A1 (es) 2013-03-14 2015-09-10 Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal.

Country Status (10)

Country Link
US (3) US9498612B2 (es)
EP (1) EP2968886A1 (es)
JP (1) JP2016514024A (es)
CN (1) CN105377355A (es)
AU (1) AU2014241396A1 (es)
BR (1) BR112015022025A8 (es)
CA (1) CA2904703A1 (es)
CL (1) CL2015002560A1 (es)
RU (1) RU2015143995A (es)
WO (1) WO2014159060A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514024A (ja) 2013-03-14 2016-05-19 ハラックス，インコーポレイテッド 爪部の感染症、疾患または障害の治療方法
US20190168016A1 (en) * 2016-02-09 2019-06-06 Luma Therapeutics, Inc. Methods, compositions and apparatuses for treating psoriasis by phototherapy
US20180092840A1 (en) * 2016-10-04 2018-04-05 The George Washington University Ultrasound-enhanced drug delivery for treatment of onychomycosis
TR201803213A2 (tr) * 2018-03-06 2018-04-24 Tambay Taskin Psori̇asi̇s tedavi̇si̇ i̇çi̇n pi̇mekroli̇mus, klobetazol ve kalsi̇potri̇ol i̇çeren topi̇kal farmasöti̇k formülasyonlar

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186196A (en) 1976-04-19 1980-01-29 Lasher Edward Abe Topical anti-fungicide preparation
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4263289A (en) 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4180058A (en) 1978-08-15 1979-12-25 Jacob Brem Method of treating pathological conditions of the nail
US4250164A (en) 1979-04-09 1981-02-10 Bernstein Joel E Method of treating psoriasis of the nails and composition
CY1410A (en) 1979-08-22 1988-04-22 Sandoz Ag Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
DE3262386D1 (en) 1981-06-06 1985-03-28 Pfizer Ltd Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
SU1122323A1 (ru) 1982-05-26 1984-11-07 Научно-Исследовательская Лаборатория Металлоостеосинтеза С Клиникой Им.А.Сеппо Способ лечени остеомиелита
US4490395A (en) 1983-04-18 1984-12-25 Warner-Lambert Company Chewing gum with improved stability
JPS59222406A (ja) 1983-06-01 1984-12-14 Teijin Ltd 歯周疾患治療用製剤及びその製造法
US4685883A (en) 1983-09-12 1987-08-11 Jernberg Gary R Local delivery of chemotherapeutic agents for the treatment of periodontal disease
US4892736A (en) 1983-10-07 1990-01-09 The Forsyth Dental Infirmary For Children Intra-pocket drug delivery devices for treatment of periodontal diseases
US4636520A (en) 1984-07-16 1987-01-13 Fujisawa Pharmaceutical Co., Ltd. Antifungal composition employing pyrrolnitrin in combination with an imidazole compound
US4568536A (en) 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4919939A (en) 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
IL78826A (en) 1986-05-19 1991-05-12 Yissum Res Dev Co Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5547988B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Alleviating signs of dermatological aging with glycolic acid lactic acid or citric acid
US5002769A (en) 1987-03-13 1991-03-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for the sustained-release of chlorhexidine
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
US5002938A (en) 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
US5110809A (en) 1988-03-21 1992-05-05 Bristol-Myers Squibb Company Antifungal gel formulations
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5059123A (en) 1990-05-14 1991-10-22 Jernberg Gary R Periodontal barrier and method for aiding periodontal tissue regeneration
US5197882A (en) 1990-05-14 1993-03-30 Gary R. Jernberg Periodontal barrier and method for aiding periodontal tissue regeneration agents
US5063049A (en) 1990-06-11 1991-11-05 Calvert Billings Disinfectant nail polish remover
CA2065156A1 (en) 1990-07-03 1992-01-04 Richard L. Dunn Intragingival delivery systems for treatment of periodontal disease
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
DE4212105A1 (de) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
RU2062607C1 (ru) 1992-09-28 1996-06-27 Медико-санитарная часть Государственного производственного объединения "Воткинский завод" Способ лечения ногтевого панариция
US5464610A (en) 1992-10-15 1995-11-07 Schering-Plough Healthcare Products, Inc. Method for treating onychomycosis
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
DE19518262A1 (de) 1995-05-18 1996-11-21 Hoechst Ag Die Verwendung von Glyceryltriacetat zur Behandlung von Onychomykosen
US5391367A (en) 1993-07-28 1995-02-21 Pfizer Inc. Antifungal nail solution
US5916545A (en) 1993-07-28 1999-06-29 Pfizer Inc. Antifungal nail solution
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
ES2233933T3 (es) 1993-10-07 2005-06-16 Odontex, Inc. Potenciadores de la absorcion para formulaciones farmaceuticas topicas.
US5487776A (en) 1994-03-17 1996-01-30 Nimni; Marcel Anti-fungal nail lacquer and method therefor
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
RU2083224C1 (ru) 1994-09-30 1997-07-10 Сергей Федорович Подчайнов Противогрибковое средство для стоп
US5641501A (en) 1994-10-11 1997-06-24 Ethicon, Inc. Absorbable polymer blends
KR960016882A (ko) 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
US5597849A (en) 1994-11-14 1997-01-28 Medical Polymer Technologies, Inc. Stick formulations for topical drug delivery of therapeutic agents and uses thereof
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5587152A (en) 1994-12-15 1996-12-24 Mackles; Leonard Clear solid topical deodorant compositions comprising a water-insoluble ester of a water-soluble acid
JP3749279B2 (ja) 1995-03-01 2006-02-22 日産化学工業株式会社 爪用抗真菌剤
RU2197964C2 (ru) 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
PL184531B1 (pl) 1995-06-07 2002-11-29 Alkermes Inc Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii
FR2740335B1 (fr) 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5648389A (en) 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use
US6008173A (en) 1995-11-03 1999-12-28 Colgate-Palmolive Co. Bar composition comprising petrolatum
US5696105A (en) 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
FR2756493B1 (fr) 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
WO1998046782A1 (en) 1997-04-15 1998-10-22 Monsanto Company Methods of pha extraction and recovery using non-halogenated solvents
US5894020A (en) 1997-04-18 1999-04-13 Concha; Jose Soap composition containing antifungal agent
AU7582398A (en) 1997-05-19 1998-12-11 Rosemarie Scivoletto Composition for treating skin conditions
US6123957A (en) 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US5993790A (en) 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
DE19836436A1 (de) 1997-08-20 1999-03-11 Akzo Nobel Nv Verfahren zur Herstellung von biologisch abbaubaren Fasern und Filamenten
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US5947956A (en) 1997-11-04 1999-09-07 Karell; Manuel Leon Laser apparatus for making holes and etchings
ATE238751T1 (de) 1998-02-09 2003-05-15 Macrochem Corp Antimykotischer nagellack
US6727401B1 (en) 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US6231840B1 (en) 1998-02-13 2001-05-15 Carol J. Buck Compositions and methods for the topical treatment of nail fungi conditions
KR100382568B1 (ko) 1998-02-23 2003-05-09 메사츄세츠 인스티튜트 어브 테크놀로지 생물분해성 형상기억 중합체
US6143794A (en) 1998-04-17 2000-11-07 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US20030007939A1 (en) 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
US6264927B1 (en) 1998-08-27 2001-07-24 Elmer P. Monahan Topical solution and method for the treatment of nail fungus
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US6270472B1 (en) 1998-12-29 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing
WO2000041688A1 (en) 1999-01-11 2000-07-20 The Board Of Regents Of The University And Community College System Of Nevada Use of an amiodarone compound as antifungal agent
US6517863B1 (en) 1999-01-20 2003-02-11 Usbiomaterials Corporation Compositions and methods for treating nails and adjacent tissues
US6344190B1 (en) 1999-02-08 2002-02-05 Board Of Trustees Of Michigan State University Method and compositions for treatment of fungal nail disease
KR100372751B1 (ko) 1999-11-16 2003-02-17 한국과학기술원 생체조직공학용 다공성 생분해성 고분자 지지체의 제조방법
EP1165749B1 (en) 1999-03-18 2007-08-01 Korea Advanced Institute Of Science And Technology Method for preparing porous, biodegradable and biocompatible, polymeric scaffolds for tissue engineering
EP1212093B1 (en) 1999-08-26 2004-07-07 Ganeden Biotech, Inc. Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US6386869B1 (en) 2000-02-18 2002-05-14 Peter J. Zegarelli Oral therapeutic delivery appliance
US6450938B1 (en) * 2000-03-21 2002-09-17 Promex, Llc Brachytherapy device
US7074392B1 (en) 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
US7087249B2 (en) 2001-04-23 2006-08-08 Nucryst Pharmaceuticals Corp. Treatment of mucosal membranes
AU2001291308A1 (en) 2000-09-14 2002-03-26 The Research Foundation Of State University Of New York At Stony Brook Methods and compositions for treating nail fungus
US6673756B2 (en) 2000-09-20 2004-01-06 Symrise Gmbh & Co. Kg Multiphase soaps
RU2196555C2 (ru) 2000-11-27 2003-01-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ хирургического лечения открытоугольной глаукомы
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6676953B2 (en) 2001-01-26 2004-01-13 Don L. Hexamer Antifungal composition and method for human nails
US6878365B2 (en) 2001-03-10 2005-04-12 James Edward Brehove Topical application for treating toenail fungus
KR100354828B1 (ko) 2001-03-12 2002-10-05 주식회사 씨엠리서치 생분해성 폴리에스테르의 제조방법 및 그에 의해 제조된생분해성 폴리에스테르
GB0108082D0 (en) 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
WO2002092661A1 (en) 2001-05-11 2002-11-21 Ap Pharma, Inc. Peg-poe, peg-poe-peg, and poe-peg-poe block copolymers
US6664292B2 (en) 2001-06-04 2003-12-16 Mark H. Bogart Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
US7615234B2 (en) 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
AU2002341959A1 (en) 2001-10-04 2003-04-14 Case Western Reserve University Drug delivery devices and methods
US20030130225A1 (en) 2001-10-16 2003-07-10 Nawaz Ahmad Novel methods of treating local fungal and bacterial infections
CA2468539C (en) 2001-10-22 2013-01-08 Michael A. Repka Delivery of medicaments to the nail
US20030207971A1 (en) 2001-11-27 2003-11-06 React Of Delafield Llc Emollient gel
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
US7135194B2 (en) 2002-09-27 2006-11-14 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
US20070014743A1 (en) 2002-09-27 2007-01-18 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
US8404751B2 (en) 2002-09-27 2013-03-26 Hallux, Inc. Subunguicide, and method for treating onychomycosis
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
DK1635770T3 (da) 2003-03-21 2009-08-03 Nexmed Holdings Inc Antifungal neglelak og anvendelsesmetode
CN100350878C (zh) 2003-03-27 2007-11-28 泰尔茂株式会社 体液采集器
US7214206B2 (en) 2003-04-03 2007-05-08 Valera Pharmaceuticals, Inc. Implanting device and method of using same
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
US7588559B2 (en) 2004-07-01 2009-09-15 W&H Dentalwerk Bürmoos GmbH Injection systems
US7395790B2 (en) 2004-11-18 2008-07-08 S&S Cycle, Inc. Reed valve breather for evolution engine
US20060112503A1 (en) 2004-11-29 2006-06-01 The Procter & Gamble Company Solid personal care composition
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
AU2005314426A1 (en) 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US9757552B2 (en) 2005-01-24 2017-09-12 Merck Sharp & Dohme B.V. Applicator for inserting an implant
CA2498623A1 (en) 2005-02-18 2006-08-18 Qlt Inc. Treatment of onychomycosis
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2007084230A2 (en) 2005-12-13 2007-07-26 William Krause Automated biopsy and delivery device
DE102006018827A1 (de) 2006-04-22 2007-10-31 Bayer Healthcare Ag Applikator mit auswechselbarem Behälter
WO2008121709A1 (en) 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
US20090093787A1 (en) 2007-04-20 2009-04-09 Jennifer Barbour Ergonomic syringe
US20080287912A1 (en) 2007-05-14 2008-11-20 Horrigan Corporation Method, Device And Formulation For The Treatment Of Nail Disorders
AU2008300018A1 (en) 2007-09-07 2009-03-19 Qlt Inc. Insertion and extraction tools for lacrimal implants
US8221358B2 (en) 2007-11-20 2012-07-17 Warsaw Orthopedic, Inc. Devices and methods for delivering drug depots to a site beneath the skin
WO2011063349A1 (en) 2009-11-20 2011-05-26 Talima Therapeutics, Inc. Devices for implanting compositions and methods and kits therefor
CA2785549A1 (en) 2009-12-22 2011-07-21 Talima Therapeutics, Inc. Antifungal therapy
JP2016514024A (ja) 2013-03-14 2016-05-19 ハラックス，インコーポレイテッド 爪部の感染症、疾患または障害の治療方法

Also Published As

Publication number Publication date
US20170036004A1 (en) 2017-02-09
US10456568B2 (en) 2019-10-29
US20150238744A1 (en) 2015-08-27
CN105377355A (zh) 2016-03-02
RU2015143995A (ru) 2017-04-20
JP2016514024A (ja) 2016-05-19
BR112015022025A8 (pt) 2019-12-10
BR112015022025A2 (pt) 2017-07-18
AU2014241396A1 (en) 2015-09-17
US9498612B2 (en) 2016-11-22
US9375558B2 (en) 2016-06-28
WO2014159060A1 (en) 2014-10-02
CA2904703A1 (en) 2014-10-02
US20140276477A1 (en) 2014-09-18
EP2968886A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
CO2017011437A2 (es) Composiciones de nanopartículas para terapia sostenida
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
BR112018003984A2 (pt) anticorpos
CL2015003022A1 (es) Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
BR112016010564A2 (pt) terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
BR112015020584A2 (pt) métodos para o tratamento de artrite psoriática usando apremilast
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
CL2019000493A1 (es) Sistema y método para terapia médica controlada.
CL2015002560A1 (es) Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal.
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
CL2017000050A1 (es) Terapia de combinación para el cáncer
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo